Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

PSA Doubling Time and Absolute PSA Predict Metastasis-free Survival in Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.

Markowski MC, Chen Y, Feng Z, Cullen J, Trock BJ, Suzman D, Antonarakis ES, Paller CJ, Rosner I, Han M, Walsh PC, Partin AW, Eisenberger M.

Clin Genitourin Cancer. 2019 Aug 21. pii: S1558-7673(19)30251-4. doi: 10.1016/j.clgc.2019.08.002. [Epub ahead of print]

PMID:
31530439
2.

PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.

Roberts SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke H.

Mayo Clin Proc. 2001 Jun;76(6):576-81.

PMID:
11393495
3.

Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.

Stephenson AJ, Shariat SF, Zelefsky MJ, Kattan MW, Butler EB, Teh BS, Klein EA, Kupelian PA, Roehrborn CG, Pistenmaa DA, Pacholke HD, Liauw SL, Katz MS, Leibel SA, Scardino PT, Slawin KM.

JAMA. 2004 Mar 17;291(11):1325-32.

PMID:
15026399
4.

Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database.

Antonarakis ES, Chen Y, Elsamanoudi SI, Brassell SA, Da Rocha MV, Eisenberger MA, McLeod DG.

BJU Int. 2011 Aug;108(3):378-85. doi: 10.1111/j.1464-410X.2010.09878.x. Epub 2010 Nov 23.

5.
6.

The effect of the frequency and duration of PSA measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer.

Paller CJ, Olatoye D, Xie S, Zhou X, Denmeade SR, Eisenberger MA, Antonarakis ES, Carducci MA, Rosner GL.

Prostate Cancer Prostatic Dis. 2014 Mar;17(1):28-33. doi: 10.1038/pcan.2013.40. Epub 2013 Oct 8.

7.

Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy?

Castellucci P, Ceci F, Graziani T, Schiavina R, Brunocilla E, Mazzarotto R, Pettinato C, Celli M, Lodi F, Fanti S.

J Nucl Med. 2014 Sep;55(9):1424-9. doi: 10.2967/jnumed.114.138313. Epub 2014 Jun 16.

8.

PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy.

Giovacchini G, Picchio M, Scattoni V, Garcia Parra R, Briganti A, Gianolli L, Montorsi F, Messa C.

Eur J Nucl Med Mol Imaging. 2010 Jun;37(6):1106-16. doi: 10.1007/s00259-010-1403-7. Epub 2010 Mar 20.

PMID:
20306038
9.

Radical prostatectomy for clinical stage T3a disease.

Freedland SJ, Partin AW, Humphreys EB, Mangold LA, Walsh PC.

Cancer. 2007 Apr 1;109(7):1273-8.

10.

Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.

Kupelian PA, Katcher J, Levin HS, Klein EA.

Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1043-52.

PMID:
9169811
11.

Salvage radiotherapy in prostate cancer patients with biochemical relapse after radical prostatectomy : Prolongation of prostate-specific antigen doubling time in patients with subsequent biochemical progression.

Lohm G, Neumann K, Budach V, Wiegel T, Hoecht S, Gollrad J.

Strahlenther Onkol. 2018 Apr;194(4):325-332. doi: 10.1007/s00066-017-1247-1. Epub 2017 Dec 18.

PMID:
29255924
12.

[PSA and follow-up after treatment of prostate cancer].

Benchikh El Fegoun A, Villers A, Moreau JL, Richaud P, Rebillard X, Beuzeboc P.

Prog Urol. 2008 Mar;18(3):137-44. doi: 10.1016/j.purol.2007.12.010. Epub 2008 Apr 18. Review. French.

PMID:
18472065
13.

Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?

Castellucci P, Fuccio C, Rubello D, Schiavina R, Santi I, Nanni C, Allegri V, Montini GC, Ambrosini V, Boschi S, Martorana G, Marzola MC, Fanti S.

Eur J Nucl Med Mol Imaging. 2011 Jan;38(1):55-63. doi: 10.1007/s00259-010-1604-0. Epub 2010 Sep 17.

PMID:
20848281
14.

The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up.

Antonarakis ES, Feng Z, Trock BJ, Humphreys EB, Carducci MA, Partin AW, Walsh PC, Eisenberger MA.

BJU Int. 2012 Jan;109(1):32-9. doi: 10.1111/j.1464-410X.2011.10422.x. Epub 2011 Jul 20.

15.

Salvage radiation therapy improves metastasis-free survival for clinically aggressive and indolent prostate cancer recurrences after radical prostatectomy.

Jackson WC, Johnson SB, Feng FY, Hamstra DA.

Am J Clin Oncol. 2015 Aug;38(4):367-72. doi: 10.1097/COC.0b013e31829e17db.

PMID:
23822986
16.

Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy.

Ward JF, Zincke H, Bergstralh EJ, Slezak JM, Blute ML.

J Urol. 2004 Dec;172(6 Pt 1):2244-8.

PMID:
15538240
18.

Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer.

Hanlon AL, Diratzouian H, Hanks GE.

Int J Radiat Oncol Biol Phys. 2002 Jun 1;53(2):297-303.

PMID:
12023133
19.
20.

Predictors of short postoperative prostate-specific antigen doubling time for patients diagnosed during PSA era.

Lin DD, Schultz D, Renshaw AA, Rubin MA, Richie JP, D'Amico AV.

Urology. 2005 Mar;65(3):528-32.

PMID:
15780370

Supplemental Content

Support Center